E
Cingulate Inc. CING
$3.94 -$0.11-2.72% NASDAQ
Recommendation
Prev Close
$3.94
Volume
382
Avg Vol (90D)
126,333
Market Cap
$14.85M
Dividend & Yield
--
52-Week Range
$1.80 - $20.83
P/E (TTM)
--
EPS (TTM)
-$16.38
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Cingulate Inc. (NASDAQ:CING) Sees Significant Growth in Short Interest
5/5/2025 - Ticker Report
Cingulate announces results from high-dose fed/fast study of CTx-1301
4/29/2025 - The Fly
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead ...
4/29/2025 - GuruFocus
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
4/29/2025 - Globe Newswire
Cingulate Inc. (NASDAQ:CING) Short Interest Update
4/17/2025 - Ticker Report
Cingulate wins $3M grant from private foundation for third time-release drug
4/10/2025 - Bizjournals.com - Health Care News
Cingulate receives $3M grant from to accelerate development of CTx-2103
4/9/2025 - The Fly
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of ...
4/9/2025 - GuruFocus
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
4/9/2025 - Globe Newswire
Cingulate completes pre-NDA meeting with FDA on NDA for CTx-1301
4/3/2025 - TipRanks Financial Blog
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD ...
4/3/2025 - GuruFocus
Cingulate completes pre-NDA meeting with FDA on NDA for CTx-1301
4/3/2025 - The Fly
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
4/3/2025 - Globe Newswire
Cingulate Inc. (NASDAQ:CING) Sees Significant Decline in Short Interest
4/1/2025 - Ticker Report
Cingulate Inc. Reports 2024 Financial and Development Milestones
3/28/2025 - TipRanks Financial Blog
Cingulate (CING) Boosts Cash Position with $12.2 Million in Reserves
3/27/2025 - GuruFocus
Cingulate reports FY results
3/26/2025 - SeekingAlpha.com: All News
Cingulate sees cash runway sufficient into Q4
3/26/2025 - TipRanks Financial Blog
Cingulate sees cash runway sufficient into Q4
3/26/2025 - The Fly
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
3/26/2025 - Globe Newswire
Cingulate Inc. (NASDAQ:CING) Short Interest Update
3/7/2025 - Ticker Report
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN), Cingulate Inc (CING) and Veeva Systems (VEEV)
3/6/2025 - TipRanks Financial Blog
Cingulate reports safety results from final Phase 3 trials for CTx-1301
3/4/2025 - TipRanks Financial Blog
Cingulate reports safety results from final Phase 3 trials for CTx-1301
3/4/2025 - The Fly
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On ...
3/4/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$14.99M
EBIT (TTM)
-$15.65M
Net Income (TTM)
-$15.55M
Balance Sheet
Total Assets (Q)
$14.86M
Total Debt (Q)
$5.10M
Total Liabilities (Q)
$7.41M
Book Value Per Share (Q)
$2.19
Cash Flow
Cash from Operations (TTM)
-$18.45M
Cash from Investing (TTM)
-$211.80K
Cash from Financing (TTM)
$30.82M
Net Change in Cash (TTM)
$12.16M
Filings
Filing Date
Thursday, March 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
-0.21
7-Day Total Return
-5.74%
30-Day Total Return
-4.83%
60-Day Total Return
-13.79%
90-Day Total Return
-18.26%
Year to Date Total Return
-22.75%
1-Year Total Return
-63.03%
2-Year Total Return
-98.51%
3-Year Total Return
-98.60%
5-Year Total Return
--
52-week Low
Aug 14, 2024 - $1.80
52-week High
Aug 16, 2024 - $20.83
Valuation
Market Cap
$14.85M - Nano Cap
Enterprise Value
$7.74M
Price/Sales (TTM)
--
Price/Book (Q)
1.80
Dividends and Shares
Shares Outstanding
3.29M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.cingulate.com
Phone Number
913 942 2300
Address
1901 West 47th Place
Kansas City, KS 66205
Country
United States
Year Founded
2012
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company... more
NASDAQ 05/07/2025 4:00PM Eastern Quotes delayed